Explore peptide knowledge

Abaloparatide is a synthetic 34-residue analog of human parathyroid hormone-related protein, PTHrP(1–34), designed to activate the parathyroid hormone type 1 receptor. Intermittent subcutaneous exposure produces an osteoanabolic response by stimulating osteoblast activity and increasing bone formation. The molecule contains an α-aminoisobutyric-acid substitution and is distinct from endogenous PTHrP and from teriparatide. Regulatory authorization is product- and jurisdiction-specific: the FDA-approved TYMLOS label covers defined high-fracture-risk postmenopausal women and men, while the EMA-authorized ELADYNOS indication is for postmenopausal women at increased fracture risk.

Afamelanotide is a melanocortin peptide analog. The research record considers pigmentation biology and clinical outcomes in erythropoietic protoporphyria, alongside distinct exploratory questions such as UV responses and vitiligo. These settings should be kept separate.

AOD-9604 is a modified peptide derived from the C-terminal region of human growth hormone and was developed to investigate lipolytic and anti-obesity effects while attempting to avoid the broader growth-promoting actions of full-length growth hormone.

Bivalirudin is a synthetic 20-residue peptide anticoagulant derived conceptually from the thrombin-binding properties of hirudin. Its N-terminal D-phenylalanine-containing sequence binds the catalytic site of thrombin while a C-terminal region engages thrombin’s fibrin-recognition exosite; thrombin can subsequently cleave the molecule, contributing to reversible inhibition. It acts directly on circulating and clot-bound thrombin without requiring antithrombin. The molecule is established in percutaneous coronary intervention, while use in extracorporeal membrane oxygenation, cardiopulmonary bypass, pediatric procedures, and other settings has a different and often off-label evidence and regulatory context.

BPC-157 is a synthetic 15-amino-acid peptide derived from a sequence associated with gastric proteins. Experimental studies report effects on angiogenesis, nitric-oxide signaling, inflammatory pathways, and tissue repair, but the proposed mechanisms are not established as therapeutic mechanisms in humans.

Bremelanotide is a melanocortin receptor agonist peptide studied in sexual-desire disorders. The relevant clinical populations, outcome measures, and treatment settings must be distinguished from other melanocortin compounds.

Cagrilintide is an amylin analog investigated for weight management, both alone and in combinations such as CagriSema. Evidence for the single agent must be separated from evidence for the combination.

Carbetocin is a synthetic long-acting oxytocin analog and agonist at the oxytocin receptor. Structural changes—including a thioether bridge and O-methyltyrosine substitution—slow enzymatic degradation relative to oxytocin. In obstetric use it stimulates uterine smooth-muscle contraction after delivery; authorization, route, dose, and eligible population remain product- and jurisdiction-specific. Intranasal developmental research in Prader–Willi syndrome is a distinct investigational context and is not evidence of an obstetric product’s authorization for that use.

CJC-1295 is a modified growth-hormone-releasing hormone analog designed to resist enzymatic degradation and, in its drug-affinity-complex form, bind circulating albumin. Early studies show prolonged stimulation of growth hormone and IGF-1, but biomarker elevation is not equivalent to demonstrated clinical benefit.

Desmopressin is a synthetic analog of arginine vasopressin modified by deamination at position 1 and D-arginine at position 8. It preferentially activates renal V2 receptors, increasing collecting-duct water reabsorption through aquaporin-2 trafficking; V2-mediated endothelial release of von Willebrand factor and factor VIII underlies selected haemostatic uses. Clinical effects and risks differ materially by indication, dose, route, formulation, renal function, fluid intake, age, and concomitant medicines.

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist studied in type 2 diabetes. WPF organizes the available work by glycemic outcomes, cardiovascular outcomes, comparisons, and safety. Results depend on the population, comparator, dose, and follow-up period.

Mitochondria-targeting aromatic-cationic tetrapeptide that interacts with cardiolipin; evidence is separated by disease and endpoint.

Epitalon (also transliterated Epithalon) is the tetrapeptide Ala-Glu-Asp-Gly associated with Russian peptide-bioregulator research. Proposed effects include modulation of gene expression, circadian biology, oxidative stress, and telomerase-related pathways, but mechanisms and clinical relevance remain uncertain.

Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. WPF organizes its research by formulation, type 2 diabetes outcomes, comparative studies, safety and tolerability, and other investigated questions. Formulation and dosing schedules differ across studies, so results from one preparation or population should not automatically be generalized to another.

GHK-Cu is the copper(II) complex of the endogenous tripeptide glycyl-L-histidyl-L-lysine. It binds copper and has been studied in copper handling, extracellular-matrix remodeling, fibroblast activity, inflammatory signaling, antioxidant responses, and wound repair. Effects are formulation-, concentration-, route-, and model-dependent.

Synthetic growth-hormone secretagogue and ghrelin-receptor agonist studied in endocrine challenge testing.

Synthetic growth-hormone secretagogue and ghrelin-receptor agonist studied in endocrine and metabolic research.

Glucagon is an endogenous peptide hormone central to glucose regulation. The hormone, glucagon-containing medicines, and drugs that target glucagon or GLP-1 pathways answer different biological and clinical questions.

Synthetic hexapeptide growth-hormone secretagogue acting principally through the ghrelin receptor.

Humanin is a mitochondrial-derived peptide investigated in cellular stress and metabolic biology. Associations involving circulating humanin and experiments with related fragments do not establish a treatment in humans.

Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue that activates the ghrelin receptor (GHSR1a). It was designed to stimulate pulsatile growth-hormone release with less ACTH or cortisol stimulation than some earlier secretagogues.

Kisspeptin refers to a family of neuropeptides involved in reproductive neuroendocrine signaling. The parent peptide family, named fragments, and synthetic analogs should not be treated as interchangeable interventions.

Bioactive C-terminal kisspeptin fragment that activates KISS1R and hypothalamic-pituitary-gonadal signaling.

KPV is the C-terminal tripeptide Lys-Pro-Val of alpha-melanocyte-stimulating hormone. Preclinical studies associate KPV and related analogs with anti-inflammatory and antimicrobial effects, including modulation of NF-kB-linked signaling and epithelial inflammatory responses.

Lanreotide is a synthetic cyclic octapeptide somatostatin analog with high affinity particularly for somatostatin receptor subtypes 2 and 5. Receptor activation suppresses growth-hormone secretion and multiple gastroenteropancreatic hormones and can exert antiproliferative effects in selected somatostatin-receptor-expressing neuroendocrine tumors. Depot and Autogel formulations provide prolonged exposure; approved indications and administration requirements vary by product and jurisdiction.

Leuprolide is a synthetic nonapeptide agonist of the gonadotropin-releasing hormone receptor. Initial continuous exposure can transiently increase luteinizing hormone, follicle-stimulating hormone, and gonadal steroid concentrations; sustained depot exposure then desensitizes pituitary GnRH signaling and suppresses gonadal steroid production. This biphasic action supports product-specific uses in prostate cancer, central precocious puberty, endometriosis, and uterine fibroids, while stimulation-test and assisted-reproduction contexts use different timing and objectives.

Linaclotide is a guanylate cyclase-C agonist peptide studied for gastrointestinal symptoms. Constipation-related conditions, age groups, and bowel-preparation studies are distinct settings and should be interpreted separately.

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist investigated in type 2 diabetes and weight management. WPF separates findings by dose, population, indication, comparator, and endpoint so that one result is not generalized to every setting.

Human cathelicidin antimicrobial peptide with membrane-active, immunomodulatory, and wound-biology roles.

Mazdutide is a dual GLP-1 and glucagon receptor agonist investigated in metabolic disease. Weight-management and type 2 diabetes trials have different enrolled populations, regimens, comparators, and endpoints.

Synthetic cyclic melanocortin-receptor agonist studied for pigmentation and other effects.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region. Experimental work links it to cellular stress responses, AMPK-related metabolism, nuclear signaling, exercise adaptation, and age-associated physiology.

Octreotide is a synthetic cyclic octapeptide analog of somatostatin with greater metabolic stability and longer action than endogenous somatostatin. It binds predominantly somatostatin receptor subtypes 2 and 5, suppressing growth hormone and several gastroenteropancreatic hormones and secretions; effects therefore vary by receptor expression, disease, route, and formulation. Immediate-release injection, depot injection, and delayed-release oral products have distinct pharmacokinetics and regulatory labeling.

Oxytocin is an endogenous nonapeptide hormone and neurotransmitter synthesized primarily in hypothalamic neurons and released from the posterior pituitary; it also acts locally in reproductive tissues and the central nervous system. By activating the oxytocin receptor, a G-protein-coupled receptor, it promotes uterine smooth-muscle contraction and myoepithelial contraction for milk ejection. Synthetic oxytocin is an established obstetric medicine, while many behavioral and neuropsychiatric applications remain investigational and context-dependent.

Pemvidutide is a dual GLP-1 and glucagon receptor agonist investigated in metabolic dysfunction-associated steatohepatitis and related metabolic outcomes. Liver histology, noninvasive markers, weight, and cardiovascular risk factors are distinct endpoints.

Pramlintide is an amylin analog investigated in metabolic care. Evidence about this specific compound must be separated from evidence about newer long-acting amylin analogs and combinations.

Retatrutide (LY3437943) is an investigational long-acting peptide engineered to activate GIP, GLP-1, and glucagon receptors. Published early-phase and phase 2 studies report glycemic, body-weight, and liver-fat effects, but retatrutide has no FDA-approved indication. Gray-market products are not validated by these studies.

Synthetic tuftsin-derived heptapeptide studied primarily in Russian-language preclinical and clinical literature.

Semaglutide is a long-acting analogue of human glucagon-like peptide-1 (GLP-1) engineered for resistance to DPP-4 degradation and prolonged albumin binding. It selectively activates the GLP-1 receptor. In humans, its pharmacologic effects include glucose-dependent stimulation of insulin secretion, reduced glucagon secretion, delayed gastric emptying, reduced calorie intake, and lower body weight. Clinical effects and approved uses depend on the formulation, indication, population, and regulatory jurisdiction; this archive separates those contexts rather than treating semaglutide as a single undifferentiated claim.

Synthetic ACTH-fragment-derived heptapeptide studied chiefly in Russian-language neurobiology and clinical literature.

TB-500 is a non-standardized market name commonly associated with a synthetic fragment or derivative of thymosin beta-4. Thymosin beta-4 binds actin and has been studied in cell migration, angiogenesis, inflammation, and repair; those findings cannot automatically be attributed to every product sold as TB-500.

Teduglutide is a GLP-2 analog studied in short bowel syndrome and intestinal failure. The clinical question concerns outcomes such as parenteral support and patient experience in defined populations.

Teriparatide is the recombinant 1–34 amino-acid fragment of human parathyroid hormone and retains the receptor-active N-terminal region of PTH. Intermittent subcutaneous exposure activates PTH1 receptors in bone and kidney; in bone it increases osteoblast activity and remodeling, producing an anabolic treatment effect when used according to an approved regimen. Its effects depend on exposure pattern: intermittent therapeutic administration is not equivalent to sustained endogenous parathyroid-hormone excess. Evidence and authorization are formulation-, indication-, population-, duration-, and sequence-specific.

Tesamorelin is a stabilized N-terminally modified analog of the 44-amino-acid human growth hormone–releasing hormone. It activates pituitary GHRH receptors, increasing endogenous growth-hormone release and downstream IGF-1 signaling. In the labeled population this pathway reduces visceral adipose tissue; it is not a general weight-loss mechanism.

Thymosin alpha-1 (thymalfasin) is an N-terminally acetylated 28-amino-acid peptide originally isolated from thymic tissue and corresponding to a region of prothymosin alpha. It has context-dependent immunomodulatory effects involving dendritic-cell maturation, innate pattern-recognition signaling, T-cell function, cytokine regulation, and restoration of immune responsiveness; these mechanisms do not imply benefit for every immune or infectious condition.

Thymosin beta-4 is an endogenous peptide studied in actin-related biology and experimental tissue repair. It should be distinguished from marketed products or fragments such as TB-500, which may differ in identity and evidence.

Tirzepatide is a long-acting peptide agonist at GIP and GLP-1 receptors. Controlled programs evaluate glycemic control, chronic weight management, withdrawal, obesity-related obstructive sleep apnea, HFpEF with obesity, and MASH. Regulatory conclusions remain indication- and label-specific.

Arginine vasopressin, also called argipressin or antidiuretic hormone, is an endogenous cyclic nonapeptide synthesized in hypothalamic neurons and released from the posterior pituitary. V1a-receptor activation constricts vascular smooth muscle, V2-receptor activation promotes renal water reabsorption through aquaporin-2 trafficking, and additional receptor signaling contributes to pituitary, hemostatic, and central effects. Pharmaceutical vasopressin is used in tightly defined clinical contexts, notably as an intravenous vasopressor for vasodilatory shock in the United States; endogenous physiology, diagnostic biomarkers, receptor antagonists, analogs, and investigational intranasal research must remain distinct.

Ziconotide is a conotoxin-derived peptide studied for pain through N-type calcium-channel modulation. Evidence for a defined clinical preparation and route must be separated from broad conotoxin research and animal experiments.